International Society for Cellular Therapy (ISCT) leads roundtable with major US payors, healthcare providers and industry to initiate a collaboration to address Cell Therapy product reimbursement.
The interest of many insured US citizens was represented by
participation of payor organizations including Anthem Blue Cross Blue
Shield, LifeTrac and OptumHealth.
VANCOUVER, Sept. 29, 2011 /PRNewswire/ – In keeping with its mission to drive
the commercialization of cell therapy products and advance global
patient access, ISCT hosted its second event this year in its
Commercial Development Series, this time focusing on the timely issue
of reimbursement for cell therapy and regenerative medicine products in
the US market.
Despite the accelerating pace of clinical trials in the field, the path
for reimbursement for these innovative applications is progressing
slowly in many key markets. Reimbursement and physician acceptance are
the ultimate determination for moving new therapies into standard of
care. Until strategies and reimbursement paths are more defined, the
availability of the world’s most promising therapies could be limited
in the United States.
ISCT has taken the first steps in addressing this roadblock to
commercialization with its inaugural Reimbursement Roundtable aiming to
educate stakeholders on the scope and complexity of the issues for cell
therapy and regenerative medicine product reimbursement in the USA. By
facilitating a dialogue on the issues and implications in a
collaborative approach ISCT aims to catalyze a multidisciplinary effort
to create a sustainable model for adequate cell therapy reimbursement
for US patients.
Attendance at this first Reimbursement Roundtable held in Minneapolis,
MN, USA, September 14 2011, included leadership from the major
healthcare payor organizations, Anthem Blue Cross Blue Shield,
LifeTrac, and OptumHealth as well as US Bioservices. Athersys Inc,
Aastrom Biosciences, Inc., Baxter International, Inc, Aesculap Implant
Systems, LLC, and Pluristem Therapeutics Inc, all biotech and
healthcare companies on the verge of bringing cell therapy products to
patients with their late stage clinical trials also participated. The
perspectives of healthcare providers, research funders and advocacy
organizations were represented with participation from leading
clinicians, the California Institute for Regenerative Medicine (CIRM),
America’s Blood Centers (ABC), and ISCT’s event partner the National
Marrow Donor Program (NMDP).
“The promise of regenerative medicine is huge, but there remains
significant obstacles to overcome, of which reimbursement is critical.
Even after a new therapy is approved by a regulatory agency, if the
reimbursement system is not in place, patients may lack or have limited
access to these new treatments.”, said Richard Maziarz, MD, Medical
Director, Adult Stem Cell Transplantation Program & Center for
Hematologic Malignancies, Oregon Health & Science University Knight
“We commend ISCT for its initiative in bringing together a dynamic and
influential group of industry leaders to address Cell Therapy product
reimbursement,” said Michael Boo, chief strategy officer, NMDP. “Our
direct experience and countless clinical studies demonstrate that
unrelated donor hematopoietic cell transplants are a life-saving
therapy. Increasing access to this therapy will save countless lives
and do more to reduce health care costs than denying care.”
Ed Horwitz, M.D. PhD, Associate Professor of Pediatrics, Oncology,
Children’s Hospital of Philadelphia and President of ISCT agreed “this
latest initiative reinforces ISCT’s strategic commitment to build the
necessary alignment with academia, industry and other stakeholders to
expedite the development and maturation of the field and ultimately
bring cell therapy treatments to patients faster.”
Visit www.celltherapyfocusgroups.com for further information on the Reimbursement Roundtable agenda and
participants. A summary report on the event will be published in
Cytotherapy, the official journal of ISCT in early 2012.
The ISCT Reimbursement Roundtable launch follows the first successful
event in its Commercial Development Series on Clinical Trial Design for
Peripheral Vascular Disease and the launch of the ISCT Industry
Community in August 2010. See: www.celltherapysociety.org/index.php/about-us/media
ISCT is a global association driving the translation of scientific
research to deliver innovative cellular therapies and advancing global
patient access. Established in 1992, its membership and leadership
comprises world-class scientists, clinicians,
technologists, biotech/pharma and regulatory professionals from around
the world focused on pre-clinical and translational aspects of
developing cell therapy products.
Ã‚© 2011 International Society for Cellular Therapy. All rights
reserved. ISCT, International Society for Cellular Therapy, and the
ISCT logo are registered service marks of The International Society for
Cellular Therapy. The BEACON and lighthouse logo is a service mark of
The International Society for Cellular Therapy.
SOURCE International Society for Cellular Therapy